{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-341229","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2026-08-10T11:13:38+00:00","discovered_at":"2026-08-10T11:15:00.278937+00:00","generated_at":"2026-08-10T11:15:05.775074+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Jade Biosciences Q2 2026 net loss $55.8M; JADE101 Phase 1 data positive, cash $461M","bullets":["Q2 2026 net loss $55.8M vs $32.1M in Q2 2025; R&D $50.1M, G&A $8.9M.","Cash, equivalents, investments $461.2M as of June 30, 2026; runway into Q4 2028 after $172.5M offering.","JADE101 Phase 1: ~70% mean IgA reduction after single 700mg dose; supports every-12-week dosing; Phase 2 JUNIPER underway, Phase 3 expected H1 2027.","JADE201 Phase 1 in rheumatoid arthritis dosing began; interim data 2027. JADE301 for dermatomyositis unveiled; Phase 1 healthy volunteers expected Q4 2026.","Mark Eisner, M.D., appointed to board; company advancing pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-341229","json":"https://secwatch.observer/filing/0001193125-26-341229.json","markdown":"https://secwatch.observer/filing/0001193125-26-341229.md","text":"https://secwatch.observer/filing/0001193125-26-341229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/0001193125-26-341229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:15:05.775074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}